We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Update on cardiotoxicity evaluation during the treatment of breast cancer.
- Authors
Gae, Diana Andreea; Zob, Daniela Luminiţa; Cherciu, Nelly; Ploeşteanu, Rodica Lucia; Stănculeanu, Dana Lucia
- Abstract
The treatment of breast cancer comprises a broad variaty of antineoplastic drugs, from the classic chemotherapeutic agents such anthracyclines, cyclophosphamide, taxans, 5-fluorouracil, methotrexate, to the targeted therapies like anti-HER2/neu antibody (trastuzumab), tyrosine-kinase inhibitor (lapatinib) and endocrine drugs. These can affect the cardiovascular system, more or less, alone or in combination with other oncologic drugs or radiotherapy. Among them, the anthracyclines are recongnised to have the highest cardiotoxic potential due to their capacity of causing irreversible cardiac injuries. The aim of this review is to briefly present some of the latest published articles that studied the issue of clinical and paraclinical approach of cardiotoxicity during the treatment of breast cancer. A detailed knowledge of the cardiovascular risks and the relevant evaluation methods which can be performed during breast cancer treatment is important in order to prevent or attenuate acute or delayed cardiotoxicity, by adjusting the chemotherapeutic agents' dose and/or by initiating the appropriate cardioprotective treatment.
- Subjects
ANTINEOPLASTIC agents; BREAST cancer patients; BREAST cancer treatment
- Publication
Oncolog-Hematolog, 2017, Issue 41, p27
- ISSN
2066-8716
- Publication type
Article
- DOI
10.26416/onhe.41.4.2017.1348